Antibody Drug Conjugates Market Size & Share 2025 – 2034

Antibody Drug Conjugates Market Size

The global antibody drug conjugates market was valued at USD 12.9 billion in 2024. The market is expected to grow from USD 14.1 billion in 2025 to USD 34.1 billion in 2034, at a CAGR of 10.3% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is experiencing a strong expansion, majorly propelled by the increasing worldwide prevalence and incidence of cancer such as blood cancer, breast cancer, and urothelial cancer and bladder cancer.

For instance, as per the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths globally. The estimated number of people who were alive within five years following a cancer diagnosis was 53.5 million. Furthermore, about 1 in 5 people develop cancer in their lifetime, and approximately 1 in 9 men and 1 in 12 women die from the disease. The increasing worldwide cancer load underscores the urgent demand for more effective and targeted cancer treatments, fueling the growth of the ADC market. As cancer incidence continues to increase, especially in aging populations and emerging economies, the need for advanced therapeutics like ADCs is expected to intensify.

Antibody drug conjugate (ADC) is a cancer treatment that combines chemotherapy and targeted therapy. It is used when certain types of cancer come back after the previous treatments, or when the other treatments are not effective. These ADCs release potent chemo drugs into the cancer cells, thereby damaging and destroying these cells without affecting the healthy cells nearby. Key players driving the growth of the market include various pharmaceutical companies such as Pfizer, Roche, Daiichi Sankyo, AbbVie, AstraZeneca, and Astellas Pharma. These players are at the forefront of ADC innovation through the use of advanced antibody engineering, linker chemistry, and extremely toxic payloads to make their portfolios in the field of oncology more comprehensive.
 

Between 2021 and 2023, the antibody drug conjugates market witnessed considerable growth to reach USD 11.9 billion in 2023 from USD 10.1 billion in 2021 driven primarily by increasing prevalence of cancer as well as advances in cancer research. During this period, several ADCs received approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), broadening their clinical use across multiple cancer types, including breast, lung, and hematologic malignancies. Additionally, technological improvements in linker chemistry and cytotoxic payloads have improved stability and efficacy of drugs, thus propelling the market growth.
 

The antibody drug conjugates are targeted cancer therapies that link monoclonal antibodies to a potent cytotoxic drugs through a chemical linker. This antibody binds specifically to an antigen present on the surface of cancer cells; thus, the drug is brought directly to the tumor cell. After that, the linker is cleaved inside the cell, releasing the toxic agent to kill the cell while sparing healthy tissue. ADCs combine the selectivity of antibodies with the potency of chemotherapy, making cancer treatment more precise with fewer sideeffects.
 

Antibody Drug Conjugates Market Trends

• A key trend in the market is the rising incidence of cancer globally. As per the World Health Organization, over 35 million new cancer cases are predicted in 2050, significant increase of 77% from the estimated 20 million cases in 2022. This significant increases the urgent demand for more effective and less toxic cancer therapies. ADCs address this demand by combining the targeted antibody specificity with the aggressive cell-killing power of chemotherapy drugs, thus, giving minimal harm to the healthy tissues. As a result, these therapies are becoming a cornerstone of modern cancer management.
   
• Additionally, rapid developments in linker chemistry, payload development, and antibody engineering have had a very positive influence on the performance and safety of ADCs. Modern linkers are engineered for higher stability in the bloodstream and to release their cytotoxic payload only once the ADC reaches the tumor microenvironment.
   
• Furthermore, improvements in site-specific conjugation ensure more uniform and predictable products. Meanwhile, the use of the next-generation payloads like DNA-damaging agents and topoisomerase inhibitors is widening the therapeutic scope of ADCs over the conventional cytotoxins eventually resulting in a greater number of response cases and better patient outcomes.
   
• The ADC market is being strengthened by an expanding pipeline and a surge in regulatory approvals. More than a dozen ADCs have already gained global market authorization, such as Enhertu (trastuzumab deruxtecan), Polivy (polatuzumab vedotin), and Padcev (enfortumab vedotin), with many more in clinical development.
   
• These therapies are being tested in both hematologic and solid tumors, and their expanding indications are accelerating market adoption. Regulatory agencies are also granting priority reviews and accelerated approvals, enabling faster time-to-market for promising ADCs.
   
• Moreover, pharmaceutical and biotechnology companies are heavily investing in the research and development of ADCs. The collaborations between AstraZeneca and Daiichi Sankyo as well as Pfizer and Seagen illustrate the strategic importance of ADC collaborations. Companies are broadening their production capacities and adopting advanced conjugation technologies to meet growing global demand.
   
• Overall, as advancements continue and global access widens, ADCs are set to become one of the most powerful and transformative modalities in next-generation cancer therapy, thereby the market is expected to grow.
   

Antibody Drug Conjugates Market Analysis

Based on the product type, the global antibody drug conjugates market is segmented into Enhertu, Kadcyla, Adcetris, Padcev, Trodelvy, Polivy, and other product types. The Enhertu segment dominated the market with 29.1% market share and was valued at USD 3.8 billion in 2024.
 

• Unlike several ADCs which focus on a narrower patient set, Enhertu has secured FDA approvals for HER2 Positive breast cancer, HER2 Positive gastric and non-small cell lung cancers and even for the HER2-low tumors. This wider therapeutic applicability has increased the patient population and provided a competitive advantage over other products like Kadcyla or Adcetris.
   
• Enhertu has consistently been showing high response rates and improved overall survival during clinical trials, often outperforming existing ADCs such as Kadcyla. These results have made it a preferred choice for oncologists which has substantially added to the market share.
   
• Additionally, Enhertu has received international regulatory approvals including for early-line and later-line settings, as well as in HER2-low expressing tumors. Such widening indications have increased market potential and generated higher adoption in the newly entered regions.
   
• On the other hand, Kadcyla segment held second highest market share of 18% in 2024, driven by its sustained use in patients suffering from HER2 positive breast cancer and the associated favorable clinical outcome.
   
• Additionally, its extensive worldwide accessibility has facilitated its widespread adoption across major oncology markets.
   
• Moreover, Kadcyla's well-known dosing regimens and easy administration have contributed to steady adoption, even as newer ADCs enter the market.
   

Based on the technology, the global antibody drug conjugates market is classified into cleavable linker and non-cleavable linker. The cleavable linker segment accounted for the highest market revenue of USD 10.6 billion in 2024 and is projected to grow at a CAGR of 10.2% during the analysis period due to its superior drug delivery functions.
 

• Cleavable linkers are designed to detach the cytotoxic payload exclusively in the tumor microenvironment, which is usually facilitated by factors like enzymes, pH changes, or redox conditions. Such a targeted release ensures that the tumor cells are killed to the maximum while the healthy tissues are minimally damaged, thus giving cleavable linker ADCs a distinct clinical advantage over non-cleavable ones.
   
• Theexpansion of this segment has been supported by improvements in linker chemistry and design. The new generation of cleavable linkers is equipped with enhanced stability and fewer incidences of early payload release thus greatly contributing to the safety profile of ADCs.
   
• This has made them the first choice in numerous approved therapies, such as Enhertu and Trodelvy, which have not only shown better results in clinical trials but also have been widely accepted by oncologists.
   

• On the other hand, the non-cleavable linker segment is anticipated to witness growth at a CAGR of 10.8% over the forecast period, driven by its enhanced stability and predictable pharmacokinetics.
   
• Additionally, ongoing research and development efforts aimed at optimizing non-cleavable linker ADCs, combined with increasing adoption in specific cancer indications, are expected to contribute to steady market growth and expanding clinical applications.
   

Based on the application, the global antibody drug conjugates market is classified into breast cancer, blood cancer, urothelial cancer and bladder cancer, and other applications. The breast cancer segment accounted for the highest market revenue of USD 7.2 billion in 2024 and is projected to grow at a CAGR of 10.5% during the analysis period, driven by the substantial patient population, particularly those with HER2-positive and HER2-low tumors requiring targeted therapies.  Whereas the blood cancer segment is anticipated to witness growth at significant CAGR of 10.7% in coming years, driven by the rising prevalence of hematologic malignancies such as lymphoma and leukemia.
 

• The substantial number of patients, especially those with HER2-positive and HER2-low tumors, results in a powerful demand for targeted therapies, thus, making the breast cancer ADCs the leading revenue-generating segment.
   
• Drugs like Enhertu and Kadcyla have demonstrated high objective response rates and progression-free survival in clinical trials. The selective targeting of HER2-positive cells while leaving healthy tissue intact has reinforced their adoption, contributing substantially to market revenue growth.
   
• Breast cancer ADCs have been allowed for use in different lines of treatment, such as early-line, later-line, and HER2-low expressing tumors. This development, therefore, broadens the potential patient population, thus increasing both the number of prescriptions and market revenue.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on target type, the global antibody drug conjugates market is segmented into HER2, CD30, CD22, and other target types. The HER2 segment dominated the market with 47.1% of market share in 2024 and is expected to grow at 10.5% CAGR over the analysis period.
 

• HER2 is overexpressed in a significant proportion of breast and gastric cancers. A huge number of patients with tumors that are positive for HER2 lead to a great demand for HER2-targeted ADC therapies, thus making it a primary focus of pharmaceutical companies and contributing to the segment’s leading market share globally.
   
• Typically, HER2 ADCs use highly potent cytotoxic agents linked with both highly stable and cleavable linkers. This design feature makes the drug delivery more tumor-specific and minimizes off-target toxicity, enhancing patient safety and treatment efficacy, which contributes to the segment’s market dominance and sustained growth potential.
   
• Moreover, HER2 ADCs are not only safe but also effective when administered together with other targeted therapies, immunotherapies, or standard chemotherapies. The ability to intensify treatment effectiveness via combination regimens is broadening the clinical applications of these drugs, raising the prescription rates, and strengthens their overall market performance.
   
• On the other hand, CD30 segment is predicted to witness lucrative growth at 10.8% CAGR due to the rising prevalence of CD30-positive hematologic malignancies, including Hodgkin lymphoma and anaplastic large cell lymphoma.
   
• Targeted ADCs against CD30, such as Adcetris, have gained physicians' attention due to their high clinical efficacy and safety profiles.
   
• Additionally, ongoing research on the next-generation CD30 ADCs with better linkers and cytotoxic payloads, in combination with the worldwide access and regulatory approvals, supports strong market potential and rapid growth in the forecast period.
   

Based on end use, the global antibody drug conjugates market is classified into hospitals and clinics, oncology centers, and other end users. The hospitals and clinics segment held a market share of 57.4% in 2024 and is projected to grow at a CAGR of 10.2% during the analysis period.
 

• These centers act as the foremost points for diagnosis, treatment, and patient management, thus granting access to advanced oncology services. The well-established infrastructure, specialized oncology departments, and trained medical staff of these centers make them capable of handling complex ADC therapies.
   
• Additionally, hospitals and clinics often serve as sites for clinical trials and early access programs. Involvement in research and development activities enables them to quickly implement newly approved ADCs, thus giving patients the most up-to-date targeted therapies. Their capacity to monitor treatment outcomes closely also enhances the safety and efficacy of ADC administration, further reinforcing adoption.
   
• Furthermore, the growing awareness of precision medicine, combined with reimbursement support and high patient footfall, drives the sustained growth of this segment.
   

North America Antibody Drug Conjugates Market

The North America market dominated the market with a market share of 42.1% in 2024.
 

• North America holds a high market share in the market due to the well-developed healthcare system, a large population of cancer patients, and the presence of dominant players providing advanced cancer treatments including ADCs.
   
• The region is supported by substantial R&D investments, favorable regulatory frameworks, and early adoption of innovative therapies, which accelerate the launch and uptake of new ADC products.
   

The U.S. antibody drug conjugates market was valued at USD 4 billion and USD 4.3 billion in 2021 and 2022, respectively. The market size reached USD 5 billion in 2024, growing from USD 4.6 billion in 2023.
 

• The U.S. holds a dominant position in the market due to high number of patients with cancer and the rate of antibody drug conjugates adoption in the country.
   
• For instance, according to the American Cancer Society, in 2024, it was expected that there will be around 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S., demonstrating a massive patient population that requires advanced therapies such as ADCs.
   
• This high disease burden, in combination with a well-developed healthcare system and access to cutting-edge oncology treatments, eventually increased the use of ADCs in hospitals, cancer treatment centers, and private practice.
   

Europe Antibody Drug Conjugates Market

Europe market accounted for USD 3.6 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe holds a substantial share of the market, as this region benefits from advanced healthcare infrastructure, an increasing number of cancer cases, and a wide range of research and development activities in the field of oncology.
   
• Furthermore, Europe is one of the leading regions in the clinical development of new generation ADCs, thereby fostering innovation and quick patient access to novel therapies.
   
• Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations facilitate the development and commercialization of new drugs, thus attracting continuous growth of the market during the forecast ‍‌‍‍‌‍‌‍‍‌period.
   

Germany dominates the Europe antibody drug conjugates market, showcasing strong growth potential.
 

• Germany holds a high market share in the Europe market majorly due to high cancer prevalence. According to Robert Koch Institute, Germany had an unprecedented 74,512 new breast cancer cases in 2022, making the disease the most common for the female population.
   
• This increasing burden drives the demand for effective and safer treatment options including ADCs which in turn leads to a substantial market ‍‌‍‍‌‍‌‍‍‌growth.
   

Asia Pacific Antibody Drug Conjugates Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 11% during the analysis timeframe.
 

• The Asia Pacific region is poised for high growth in the antibody drug conjugates market, driven by the rapidly increasing prevalence of cancer and the rising demand for targeted therapies.
   
• Due‍‌‍‍‌‍‌‍‍‌ to the increasing aging populations, lifestyle changes, and more accurate diagnostic capabilities, cancer incidences in countries like China, Japan, and India have been on a rise. This growing patient base is creating substantial opportunities for the adoption of ADCs, which offer precise treatment with improved efficacy and safety profiles.
   

China antibody drug conjugates market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The country is experiencing a rising cancer burden, particularly breast, lung, and gastric cancer, which drives demand for targeted therapies like ADCs.
   
• Additionally, China benefits from a highly supportive government and favorable regulatory policies that facilitate the approval and commercialization of new ADC therapies in the country. Increasing investments by both domestic and multinational pharmaceutical companies in research, development, and clinical trials further expands the pipeline of novel ADCs.
   
• Moreover, growing awareness of precision medicine, coupled with improving reimbursement frameworks and patient access programs, also contributes to the market’s robust growth potential.
   

Latin American Antibody Drug Conjugates Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period due to its large patient population and rising cancer prevalence, particularly breast, lung, and hematologic cancers.
 

• The country benefits from an improving healthcare infrastructure, with well-established oncology centers capable of administering complex ADC therapies.
   
• Additionally, government initiatives to improve cancer care, expanding reimbursement policies, and increasing investments by multinational pharmaceutical companies in research and clinical trials contribute to the growing adoption of ADCs in Brazil.
   

Middle East and Africa antibody drug conjugates Market

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market in 2024.
 

• The market is expected to experience substantial growth driven by the government’s strong focus on healthcare modernization and oncology programs. Investments in advanced cancer treatment facilities, increasing awareness of targeted therapies among physicians and patients, and favorable regulatory frameworks facilitate rapid adoption of ADCs.
   
• Moreover, partnerships between local healthcare providers and global pharmaceutical companies, along with rising access to precision medicine, further enhance Saudi Arabia’s potential in the regional ADC market.
   

Antibody Drug Conjugates Market Share

The market is characterized by high entry barriers due to complex manufacturing, regulatory requirements, and the need for extensive clinical validation. Leading companies such as Roche, Daiichi Sankyo, Pfizer, AstraZeneca, and Astellas Pharma accounted for around 69.7% market share and maintain their competitive edge by investing heavily in R&D, developing innovative payloads and linkers, and pursuing approvals for new indications. Strategic collaborations, acquisitions, and regional expansions are common approaches to strengthen market presence. For instance, partnerships to co-develop or license ADCs allow companies to share development risks, accelerate regulatory approvals, and expand into emerging markets.
 

The competitive landscape is further shaped by continuous innovation in precision medicine, with companies leveraging biomarkers, companion diagnostics, and AI-driven analytics to improve patient selection and treatment outcomes. As a result, the market is not only expanding in size but also evolving in sophistication, emphasizing efficacy, safety, and patient-centric solutions.
 

Antibody Drug Conjugates Market Companies

Prominent players operating in the antibody drug conjugates industry are as mentioned below:

• AbbVie
• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Daiichi Sankyo
• Gilead
• GSK
• ImmunoGen
• Pfizer
• Roche
   
• AstraZeneca

AstraZeneca is a leading player in the global antibody-drug conjugates (ADC) market accounting for approximately 28.9% of market share, leveraging a robust pipeline of proprietary ADCs targeting oncology indications. Its portfolio includes several clinical-stage ADC candidates, while ongoing R&D, investments, and strategic collaborations enhance its position in targeted cancer therapies. For instance, in May 2024 AstraZeneca invested USD1.5 billion in ADC manufacturing facility in Singapore further strengthening its ability to scale production and global commercialization.
 

• Pfizer

Pfizer has significantly strengthened its ADC market presence following the acquisition of Seagen Inc., gaining access to cutting-edge ADC technology and a rich oncology pipeline. The company focuses on developing ADCs for novel targets, including CD25 and CD228, while leveraging Seagen’s experience in commercialization and clinical development. Pfizer’s strategic expansion in ADCs positions it for long-term growth in targeted cancer therapies.
 

• Roche

Roche remains a dominant force in the ADC market, driven by established products such as Kadcyla (trastuzumab emtansine) and Polivy (polatuzumab vedotin). The company benefits from strong global commercialization networks, extensive clinical trial experience, and continuous innovation in ADC technology. Roche’s leadership is reinforced by its focus on oncology solutions, making it a top player in targeted cancer therapy worldwide.
 

Antibody Drug Conjugates Industry News

• In August 2025, DATROWAY (datopotamab deruxtecan) from Daiichi Sankyo and AstraZeneca was approved in China for treating adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who had received prior endocrine therapy and at least one chemotherapy line. The approval strengthened the companies’ presence in the Chinese ADC market and expands their targeted oncology portfolio.
   
• In April 2024, Pfizer’s TIVDAK (tisotumabvedotintftv) received full approval from the U.S. Food & Drug Administration (FDA) for adult patients with recurrent or metastatic cervical cancer whose disease progressed following chemotherapy. This milestone enhanced Pfizer’s oncology portfolio by securing a commercial-stage ADC with strong survival data and supporting its long term revenue growth in targeted cancer therapies.
   
• In December 2022, Sobi and ADC Therapeutics SA announced that the European Commission (EC) granted conditional marketing authorization for Zynlonta (loncastuximab tesirine) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use in September, enabled the companies to expand their presence in the European ADC market and generate additional revenue from commercial sales.
   
• In April 2021, ADC Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved ZYNLONTA (loncastuximab tesirine-lpyl) for treating adult patients with relapsed or refractory large B-cell lymphoma who have undergone two or more lines of systemic therapy. This approval strengthened ADC Therapeutics’ presence in the U.S. oncology market and provide a revenue-generating opportunity from its first commercially available antibody-drug conjugate.
   

The antibody drug conjugates market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Enhertu
• Kadcyla
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Other product types

Market, By Technology

• Cleavable linker
• Non-cleavable linker

Market, By Application

• Breast cancer
• Blood cancer
  • Lymphoma
  • Leukemia
  • Multiple myeloma
• Urothelial cancer & bladder cancer
• Other applications

Market, By Target Type

• HER2
• CD30
• CD22
• Other target types

Market, By End Use

• Hospitals and clinics
• Oncology centers
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE